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Signaling crosstalk between tumor cells and fibro-
blasts confers proinvasive properties to the tumor
microenvironment. Here, we identify leukemia inhib-
itory factor (LIF) as a tumor promoter that mediates
proinvasive activation of stromal fibroblasts inde-
pendent of alpha-smooth muscle actin (a-SMA)
expression. We demonstrate that a pulse of trans-
forming growth factor b (TGF-b) establishes stable
proinvasive fibroblast activation by inducing LIF pro-
duction in both fibroblasts and tumor cells. In fibro-
blasts, LIF mediates TGF-b-dependent actomyosin
contractility and extracellular matrix remodeling,
which results in collective carcinoma cell invasion
in vitro and in vivo. Accordingly, carcinomas from
multiple origins and melanomas display strong LIF
upregulation, which correlates with dense collagen
fiber organization, cancer cell collective invasion,
and poor clinical outcome. Blockade of JAK activity
by Ruxolitinib (JAK inhibitor) counteracts fibroblast-
dependent carcinoma cell invasion in vitro and
in vivo. These findings establish LIF as a proinvasive
fibroblast producer independent of a-SMA and may
open novel therapeutic perspectives for patients
with aggressive primary tumors.INTRODUCTION
Malignant evolution of solid cancers relies on complex cell-to-
cell interactions sustained by a broad network of physical and
chemical mediators that constitutes the tumor microenviron-
ment (Hanahan andWeinberg, 2011). Such a cellular network in-
volves both tumor and nontumor cells embedded in a modified
extracellular matrix (ECM) rich in growth factors, chemokines,
and cytokines that supports cancer cell growth and invasive
spreading (Calvo and Sahai, 2011). Carcinoma-associated fibro-
blasts (CAFs) are the most representative noncancer cells within1664 Cell Reports 7, 1664–1678, June 12, 2014 ª2014 The Authorsthe tumor microenvironment (Calvo et al., 2013; Joyce and
Pollard, 2009), and their presence is associated with poor clinical
prognosis (Boyd et al., 2007; Lin et al., 2012; Navab et al., 2011;
Shi et al., 2012; Takahashi et al., 2011). It is clear that under the
influence of bioactive molecules within the tumor stroma, resi-
dent fibroblasts are activated and promote tumorigenesis (Bea-
cham and Cukierman, 2005; Bhowmick et al., 2004b; De Wever
et al., 2008; Kalluri and Zeisberg, 2006; Olumi et al., 1999).
Indeed, CAFs can support tumor initiation (Trimboli et al.,
2009), inflammation (Erez et al., 2010), and angiogenesis (Orimo
et al., 2005). CAFs are also responsible for proinvasive ECM re-
modeling and track formation leading to collective carcinoma
cell invasion (Gaggioli et al., 2007). Therefore, understanding
how cancer cells induce a fibroblast-dependent proinvasive
tumor microenvironment may provide key issues for prognosis
and treatment of patients with solid cancers.
Inflammation is a hallmark of cancer progression (Coussens
and Werb, 2002; Hanahan and Weinberg, 2011). It is estab-
lished that paracrine secretion of multiples molecules, including
transforming growth factor b (TGF-b), growth factors, and
proinflammatory molecules such as interleukin-6 (IL-6) family
cytokines, by cancer cells, promotes tumorigenesis (Calvo
and Sahai, 2011; Lederle et al., 2011). TGF-b family cytokines
are known to drive myofibroblast activation during wound
healing and cancer progression (Desmoulie`re et al., 1993;
Phan, 2008), but the role of stroma-specific TGF-b-dependent
signaling during cancer invasion remains, however, unclear.
Indeed, specific stromal deletion of TGF-b-receptor (TGF-br) II
in mice promotes invasive tumorigenesis (Achyut et al., 2013;
Bhowmick et al., 2004a; Franco et al., 2011). Similarly, pharma-
cological inhibition of TGF-br-I in a mouse model of chemically
induced carcinoma development represses papilloma progres-
sion toward development of aggressive carcinoma (Mordasky
Markell et al., 2010).
The role of TGF-b-dependent signaling in cancer promotion is
multifaceted, and targeting TGF-b signaling in patients has
been so far deceiving (Connolly et al., 2012). Here, we identify
the proinflammatory cytokine LIF as a proinvasive tumor micro-
environment promoter, and we show that high-level expression
of LIF correlates with poor clinical outcome for patients with
grade I and II head and neck and lung carcinomas. Produced
Figure 1. TGF-b1 Signaling Initiates and JAK Signaling Sustains Proinvasive Fibroblast Property
(A) Representative images of hematoxylin and eosin (H&E) coloration of paraffin-embedded sections of SCC12 cells in response to three distinct hCAF, head and
neck (HN), lung (lu), and breast (Br) cell cultures. I.I., invasion index; n = 3; mean ± SD; ***p < 0.001. Scale bar, 100 mm.
(B) H&E coloration of paraffin-embedded sections of SCC12 cells in response to three hDF cell cultures (hDF-1, -2, -3). I.I., invasion index; n = 3; mean ±SD; ***p <
0.001. Scale bar, 100 mm.
(legend continued on next page)
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by tumor cells from multiple origin and fibroblasts upon TGF-b1
stimulation, LIF drives fibroblast-dependent proinvasive tumor
microenvironment through regulation of actomyosin contrac-
tility independent of alpha-smooth muscle actin (a-SMA)
expression. Inhibition of JAK kinase activity by the JAK1/2
FDA-approved Ruxolitinib inhibitor blocks induction and main-
tenance of proinvasive ECM remodeling with consequent inhibi-
tion of cancer cell invasion in vitro and in vivo. These findings
disclose potential therapeutic opportunities for patients with
advanced cancer.
RESULTS
TGF-b1 Confers Proinvasive Properties to Fibroblasts
via a JAK1/STAT3-Dependent Signaling Pathway
Human CAFs isolated from head and neck squamous cell (hHN-
CAF), lung (hLu-CAF), or breast (hBr-CAF) carcinoma (Table S1)
support proinvasive ECM remodeling, as visualized in vitro by
their capacity to contract collagen gels (Figure S1A, black
bars) and human carcinoma SCC12 cell invasion (Figure 1A),
whereas human primary dermal fibroblasts (hDFs) displayed
no appreciable contractile phenotype (Figure S1B, black bars)
and failed to induce SCC12 cell collective invasion (Figure 1B).
Because the TGF-b cytokines, including TGF-b1, 2, and 3, are
known to promote myofibroblast activation during wound
healing and tumorigenesis (Desmoulie`re et al., 1993; Phan,
2008), we speculated that the TGF-b/SMAD signaling path-
way might be responsible of the hDF conversion into contrac-
tile and proinvasive human carcinoma-associated fibroblasts
(hCAF)-like cells. Indeed, in hDF, transient pulse of TGF-b1
stimulation induced both contractility (Figures 1C and S1B)
and proinvasive properties (Figures 1D and 1E), but TGF-
b-dependent signaling is dispensable for maintenance of the
proinvasive phenotype in CAFs and activated hDF (Figures
1C–1H, S1C, and S1D; SB431542, LY364947, and A83-01 in-
hibitors). In agreement with the notion that JAK kinase activity
is needed for proinvasive track formation by hHN-CAF (Sanz-
Moreno et al., 2011), we found that hLu-CAF and hBr-CAF cells
required JAK signaling to sustain their proinvasive potential
(Figures 1H and S1A–S1D; P6, Ruxolitinib, Cyt387, and Tofaci-
nib inhibitors). The possible contribution of the JAK kinase
signaling to the proinvasive properties of TGF-b1-activated
hDF was thus assessed using specific inhibitors. Similar to
hCAF cells, TGF-b1-activated fibroblasts were found to rely
on JAK but not on TGF-br-I signaling to promote matrix
contraction (Figures 1C, S1A, and S1B) and SCC12 cell collec-(C) Quantification of matrix contraction by hDF stimulated by TGF-b1 (2 ng/ml) for 7
inhibitor (P6) (n = 3 in triplicates; mean ± SD; ***p < 0.001). Bottom panel shows
(D) Quantification of SCC12 cell organotypic invasion assay index (experiments
treated with TGF-br-I inhibitor (SB431542) or JAK kinase inhibitor (P6) (n = 3; me
(E) H&E coloration of paraffin-embedded sections of organotypic invasion assay
(F) H&E coloration of paraffin-embedded sections of SCC12 cell invasion assays in
control transfection. Scale bar, 100 mm. (I.I. = Invasion index; n = 3; mean ± SD;
(G) Immunoblotting of TGF-br1, STAT3, p-STAT3, SMAD2, p-SMAD2, and tubulin
(H) H&E coloration of paraffin-embedded sections of SCC12 cells in response to
Scale bar, 100 mm. (I.I., invasion index; n = 3; mean ± SD; ***p < 0.001.)
(I) Immunoblotting of a-SMA, p-STAT3, and p-SMAD2 in three hDF (hDPF-1, -2, -3
SMAD2, and tubulin shown as controls.
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TGF-b signaling is sufficient to promote but not necessary to
sustain the proinvasive activity, a function that relies on JAK
kinase signaling. Further, according with previous results
(Sanz-Moreno et al., 2011), and similar to hHN-CAF, the TGF-
b1-activated hDF resulted to rely on JAK1/STAT3-specific
signaling to acquire ability for proinvasion track formation within
the ECM (Figures S1E–S1G). Accordingly, hCAF cells express-
ing the a-SMA marker displayed an enhanced endogenous
activity of STAT3 (Figure 1I), which correlated with their endog-
enous levels of collagen gel contractility (Figures S1A and S1B,
black histograms). Taken together, these data suggest that a
transient stimulation of hDF by TGF-b1 is sufficient to induce
the proinvasive phenotype in hCAF, which is then sustained
by a JAK1/STAT3-dependent signaling.
LIF Supports TGF-b1-Dependent Actomyosin
Contractility toward a Proinvasive Tumor
Microenvironment
We next investigated the molecular mechanisms that govern
TGF-b1-dependent JAK/STAT signaling activation. Stimulation
of hDF by TGF-b1 induces phosphorylation of STAT3 and
SMAD2 transcription factors. However, whereas SMAD2 activa-
tion occurs within 10 min, STAT3 activation is delayed up to 1 hr
(Figure 2A), which suggests involvement of distinct molecular
mechanisms. Because IL-6 cytokines are known to support
JAK/STAT activation (Kishimoto et al., 1995), transcription of
the IL6 cytokine gene family members in TGF-b1-stimulated
hDF was thus assessed by quantitative real-time PCR, that dis-
closed a 100-fold increase of LIF and 5-fold increase of IL6
mRNA steady-state levels (Figure 2B). The respective role of
these two cytokines was investigated using specific blocking
antibodies, which identified LIF as the major cytokine mediating
STAT3 phosphorylation upon TGF-b1 stimulation (Figure 2C).
Interestingly, LIF was detected in hDF cell culture medium 1 hr
after TGF-b1 stimulation, with a 24 hr peak of 200 pg/ml (Fig-
ure 2D), and, as expected, the pan-JAK inhibitor P6 blocked
the STAT3 phosphorylation induced by TGF-b1 (Figure 2C).
The involvement of LIF signaling in the TGF-b1-mediated
STAT3 phosphorylation was confirmed by small interfering
RNA (siRNA)-mediated knockdown of GP130-IL6ST. Indeed,
silencing of the common subunit receptor of the IL-6 family
cytokine GP130-IL6ST hampered STAT3 activation by TGF-b1
without affecting SMAD2 activation (Figure S2A). These results
support the conclusion that in hDF TGF-b1 relies on a
LIF/GP130-IL6ST/JAK1 signaling cascade to induce STAT3days and subsequently treated by TGF-br-I inhibitor (SB431542) and pan-JAK
scanned images of the contracted gel.
shown in E) induced by TGF-b1-activated hDF for 7 days and subsequently
an ± SD; ***p < 0.001).
s quantified in (D). Scale bar, 100 mm.
duced by hHN-CAF following TGF-br1 protein depletion. siLuc is used as RNAi
***p < 0.001.)
after RNAi-mediated TGF-br1 depletion. siLuc as control of RNAi transfection.
three hCAF (HN, Lu, and Br) in the presence of P6, SB431542, or control (Veh).
) and three hCAF (HN-CAF, Lu-CAF, and Br-CAF) cells. Immunoblot of STAT3,
Figure 2. LIF Mediates TGF-b1-Dependent
Proinvasive Fibroblast Activation
(A) Immunoblot of p-STAT3 and p-SMAD2 fol-
lowing TGF-b1 time course stimulation of hDF.
Immunoblot of STAT3, SMAD2, and tubulin as
controls.
(B) Quantification of mRNA level relative to the
control (Veh) of OSM, IL-6, G-CSF, LIF, CNTF, and
CT1 1 hr after TGF-b1-stimulation. (n = 3 in dupli-
cates; mean ± SD; ***p < 0.001.)
(C) Immunoblotting of p-STAT3 and p-SMAD2
after LIF or TGF-b1 stimulation in presence or
absence of P6 or LIF and/or IL-6 blocking anti-
bodies in hDF. Immunoblot of STAT3, SMAD2, and
tubulin as control.
(D) ELISA quantification of LIF secreted in TGF-b1-
stimulated hDF culture media. (UD, undetectable;
n = 3 in duplicates; mean ± SD; ***p < 0.001.)
(E) Quantification of matrix remodeling by hDF
stimulated by TGF-b1 or LIF in the presence or
absence of LIF (aLIF) and IL-6 (aIL6) blocking
antibodies for 7 days. (n = 3 in triplicates; mean ±
SD; ***p < 0.001.) Bottom panel shows scanned
images of the contracted gel.
(F) Quantification of SCC12 cell organotypic in-
vasion index induced by hDF stimulated by
TGF-b1 or LIF in the presence of LIF and/or IL-6
blocking antibodies (n = 3; mean ± SD, ***p <
0.001).
(G) H&E coloration of paraffin-embedded sections
of the SCC12 invasion assays quantified in (F).
Scale bar, 100 mm.activation and suggest that hDF just stimulated by LIF may
promote onset of a proinvasive microenvironment. According
with this idea, both matrix remodeling (Figure 2E) and SCC12
cell collective invasion were observed with hrLIF-stimulated
hDF (Figures 2F and 2G); further, LIF sequestration using a
specific blocking anti-LIF antibody counteracted the action of
TGF-b1 (Figures 2E–2G). In light of these observations, we
deduced that TGF-b1 specifically activates the proinvasive
properties of hDF via the LIF/GP130-IL6ST/JAK1 signaling
axis. Because JAK1 and ROCK cooperate to control actomyosin
contractility in hHN-CAF, which results in proinvasive tracks
formation within the ECM (Sanz-Moreno et al., 2011), the poten-Cell Reports 7, 1664–167tial role of the RhoA/ROCK-dependent
signaling pathway in LIF-mediated proin-
vasive fibroblast activation was investi-
gated. siRNA-mediated knockdown of
RhoA expression or pharmacological in-
hibition of Rho-kinase (ROCK) activity re-
sulted in blockade of both TGF-b1 and
LIF-dependent proinvasive hDF activity
(Figures S2B and S2C). Long-term stimu-
lation of both TGF-b and LIF cytokines
also upregulated RhoA small GTPase
and myosin light chain 2 (MLC2) proteins,
leading to an increase in MLC2 phos-
phorylation at ser19, which attests for
an increased activity (Figure S2D). Finally,forced expression of an active form of ROCK (ROCK-ER) (Croft
and Olson, 2006) following 4-hydroxytamoxifen (4OHT) treat-
ment was sufficient to induce hDF contractility (Figure S2E),
proinvasive capacity (Figures S2Fa and b), and MLC2 phos-
phorylation (Figure S2G) and also rescued the inhibitory effect
of P6 or anti-LIF antibody treatments under TGF-b1 stimulation
(Figures S2Fc and d). Taken together, these data suggest that
hDF activation by TGF-b1 or LIF requires actomyosin contrac-
tility, which is regulated by JAK signaling. In conclusion, in
fibroblasts, the proinflammatory cytokine LIF mediates TGF-
b1-dependent actomyosin contractility and proinvasive ECM
remodeling.8, June 12, 2014 ª2014 The Authors 1667
Figure 3. LIF Mediates TGF-b1-Dependent Actomyosin Contractility Independent of a-SMA Expression
(A) Immunoblotting of a-SMA, p-STAT3, and p-SMAD2 in hDF long-term stimulated (7 days) using SCC12 and SCC13 CM in the absence or presence of LIF and
TGF-b1, -2, -3 blocking antibodies. Immunoblotting of total STAT3, SMAD2, and tubulin shown as control.
(legend continued on next page)
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LIF Mediates Fibroblast Activation to Promote Invasive
Tumor Microenvironment Independent of a-SMA
Expression
Within the tumor microenvironment, secretion of growth factors
and cytokines (Garcı´a-Tun˜o´n et al., 2008; Sriuranpong et al.,
2003; Szepietowski et al., 2004; Wysoczynski et al., 2007) by
cancer cells is thought to activate the adjacent fibroblasts (Calvo
and Sahai, 2011; De Wever et al., 2008; Kalluri and Zeisberg,
2006; Phan, 2008). In our experiments, conditioned media
(CM) by SCC12 human carcinoma cell promoted both paracrine
STAT3 and SMAD2 activation in fibroblasts, whereas SCC13 cell
CM activated STAT3 but not SMAD2 phosphorylation (Figure 3A
and Table 1). SCC12 and SCC13 cells were further used to
investigate the role of TGF-b/SMAD2 and JAK/STAT3 signaling
in tumor cell-dependent proinvasive fibroblast activation and
expression of a-SMA protein, the latter being a CAF hallmark
activated in hDF by the TGF-b signaling (Desmoulie`re et al.,
1993). Both SCC12 and SCC13 CM promoted fibroblasts-
dependent collagen gel contraction and collective invasion of
SCC12 cells in vitro (Figures 3B, 3Ca–c, 3D, and S3Aa–c)
compared with human normal keratinocytes (hNK) CM as nega-
tive control (Figures 3Ca, 3D, S3Aa, and S3B). Blockade of para-
crine SMAD2 phosphorylation by an anti-TGF-b antibody to
SCC12 CM (Figure 3A) had no effect on proinvasive fibroblast
activation (Figures 3Cd,e and 3D), whereas addition of either a
specific LIF-blocking antibody (Figures 3A, 3Cf and g, and 3D)
or the ROCK inhibitor Y27632 (Figures S3Ad and e and S3B)
completely abrogated the action of SCC12 and SCC13 CM.
Importantly, a-SMA expression, which depends on TGF-b
signaling independently of LIF (Figure 3E), was induced by the
SCC12 CM (Figures 3A, 3F, and 3G) but not by the SCC13 CM
that activated fibroblasts STAT3 only through LIF secretion (Fig-
ures 3A, 3F, and 3G). Both SCC12 and SCC13 CM increased
MLC2 protein levels and activity, which specifically depended
on LIF secretion (Figure S3C). Thus, in hDF, a-SMA upregulation
appears to be uncoupled from acquisition of proinvasive capac-
ity, which, on the contrary, is conferred by the ‘‘tumoral’’ LIF that
relies on the crosstalk between JAK/STAT and Rho/ROCK/
MLC2 signaling pathways. This hypothesis was verified using
the CAL33 cell line, whose CM neither contains LIF nor activates
hDF proinvasiveness (Figures 3H, 3I, and S3G; Table 1). Indeed,
hDF maintained in CM from CAL33 cells engineered to secrete
transgenic hLIF (CAL33-LIF; Figure S3D) showed paracrine acti-(B) Quantification of gel contraction by hDF cells cultured in the presence of SCC1
(aTGF-b; gray histograms) or for LIF (aLIF; white histogram) at 10 mg/ml of block
(C) H&E coloration of paraffin-embedded sections of SCC12 cell organotypic invas
SCC13 (c) depleted for either TGF-b1, -2, -3 (aTGF-b; d and e) or LIF (aLIF; f and
(D) Quantification of SCC12 cell invasion index from (C) (n = 3; mean ± SD; ***p <
(E) Immunoblot of a-SMA protein expression in hDF stimulated by either TGF-b1
7 days. Tubulin shown as control.
(F) Histograms represent quantification of a-SMA-positive hDF 5 days after stim
(G) Representative confocal merged images of a-SMA and DAPI staining in hD
SB431542 inhibitors. Scale bar, 50 mm.
(H) Immunoblotting of p-STAT3 and p-SMAD2 in hDF after short-term stimulation
antibodies. CAL33 were stimulated by TGF-b1 during 48 hr, and conditioned m
noblotting of total STAT3, SMAD2, and tubulin shown as controls.
(I) Quantification of gel contraction by hDF grown in the presence of control (veh
tograms) depleted for LIF (aLIF; gray) or TGF-b1, -2, -3 (aTGF-b1, -2, -3; white) a
Cvation of matrix remodeling (Figure S3E) and STAT3 phosphory-
lation (Figure S3F). Also, CAL33-LIF CM induced proinvasive
fibroblast conversion that was blocked by addition of either a
LIF-specific blocking antibody (Figures S3G and S3H) or the
Y27632 ROCK inhibitor (Figures S3I and S3J). Because TGF-b
was found to stimulate LIF production in hDF, the capacity of
TGF-b-dependent signaling to induce LIF secretion by tumor
cells was investigated. Stimulation of CAL33 cells by TGF-b1 re-
sulted in LIF secretion, which promoted both STAT3 activation
and contractility in hDF (Figures 3H and 3I). Moreover, addition
of a LIF-specific blocking antibody to CM of TGF-b1-stimulated
CAL33 resulted in complete inhibition of both STAT3 phosphor-
ylation and matrix remodeling (Figures 3H and 3I). We thus
concluded that in human tumors, including skin, head and
neck, lung, colon, and breast carcinomas as well as melanomas
(Table 1), LIF signaling mediates onset of a proinvasive microen-
vironment by proinvasive fibroblast activation and actomyosin
contractility regulation independent of a-SMA expression.
LIF and JAK Kinase Signaling Drive Invasive Tumor
Microenvironment in Breast Carcinomas
The role of LIF production by tumor cells during invasive tumor
ECM remodeling was then investigated in vivo. LIF secretion
was first monitored in a panel of mouse breast carcinoma cell
lines spanning from a poorly tumorigenic to a highly invasive
phenotype (Aslakson and Miller, 1992; Yang et al., 2004). High
in vitro LIF secretion levels were found with 4T07, 410.4, and
4T1 invasive cancer cells, whereas LIF secretion was low in
67NR noninvasive tumor cells (Figure 4A). In vitro, LIF production
by mouse tumor cells correlated with potential to induce
contractility in mouse fibroblasts (Figure S4A). LIF low-producer
(67NR) and LIF high-producer (410.4) mouse breast carcinoma
cells were then injected into mammary fat pads of syngeneic
BALB/c female mice. Thirty days after implantation, mice
were sacrificed, and primary tumors were analyzed by immuno-
histochemistry. Strong LIF-specific staining was exclusively
observed in the primary tumor mass generated by 410.4 cells
(Figures 4Ba and b) that correlated with sustained STAT3 activa-
tion in 410.4 but not in 67NR tumors both in vivo (Figures 4Bc
and d) and in vitro (Figure 4C), which identify in LIF secreted by
the tumor cells the major cytokine driving STAT3 activation in
fibroblasts. In vitro stimulation of mouse dermal fibroblasts by
CM of 410.4 cells resulted in SMAD2 activation and a-SMA2 or SCC13 CM in control (black histograms) depleted for either TGF-b1, -2, -3
ing antibodies. (n = 3 in triplicates; mean ± SD. ***p < 0.001 and **p < 0.01.)
ion assays in the presence of hDF cells cultured in CM. hNK (a), SCC12 (b), and
g). Scale bar, 100 mm.
0.001).
or LIF in presence or absence of P6 inhibitor and LIF blocking antibody after
ulation by tumor cell conditioned media (n = 3; mean ± SD; ***p < 0.001).
F stimulated by SCC12 and SCC13 CM in presence or absence of P6 and
by control (veh.) or CAL33 CM in absence or presence of LIF or TGF-b blocking
edia was collected 24 hr after multiple washes in 0.5% serum DMEM. Immu-
.) or TGF-b1-stimulated CAL33 conditioned media (CM) in control (black his-
t 10 mg/ml of blocking antibodies (n = 3 in triplicates; mean ± SD. ***p < 0.001).
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Table 1. LIF Production by Carcinoma Cells from Different Origins Mediates Proinvasive Fibroblast Activation
Cancer Cell
Lines
STAT3-Y705
in Fibroblastsa
SMAD2-S465/467
in Fibroblastsa
Fibroblasts Contractile and Proinvasive Phenotypeb
LIF ELISA (pg/ml)cVeh SB 431542 P6 Ruxo
aIL6
(10 mg/ml)
aLIF
(10 mg/ml)d
aTGF-b
(10 mg/ml)
Human OSCC
hPK          UD
SCC12 ++ ++ + +   +  + 129.05 ± 12.4
SCC13 ++  + +   +  + 276.64 ± 18.6
SCC25 + ++ + +   +  + 48.11 ± 3.05
CAL27 ++ ++ + +   +  (50) + 400.06 ± 22.12
CAL33          UD
CAL60 ++ + + +   +  + 77.33 ± 4.24
CAL166 ++ + + +   +  + 84.14 ± 6.32
Detroit562 + ++ + +   +  + 102.97 ± 8.43
Human Colon Carcinoma
LS174 ++ + + +   +  + 185.29 ± 9.87
Human Lung Carcinoma
A549 ++ + + +   +  + 95.11 ± 6.49
Human Breast Carcinoma
MDA-MB-231 +++ ++ + +   +/ +/ + 216.79 ± 15.32
MDA-MB-468 ++ ++ + +   + + + 64.34 ± 4.54
Human Melanoma
A375P ++ + + +   +  + 276.69 ± 18.12
A375M2 +++ ++ + +   +  (50) + 545.38 ± 32.87
Mel501          UD
Sbcl2       ND  ND 6.78 ± 2.32
WM35 ++  + +   ND  ND 403 ± 30.32
WM278 + + + +   ND  ND 98.07 ± 7.3
WM793 + + + +   ND  ND 251.13 ± 13
Mel1205 ++ ND + +   ND  ND 198.46 ± 65
Human Engineered Cell Line
CAL33_mock          UD
CAL33_LIF +++  + +   + +(50) + 1,176.03 ± 86.5
Murine Breast Carcinoma
67NR    ND  ND  ND 14.5 ± 20.51
4T07 ++ +/ + ND  ND  ND 603.09 ± 49.54
410.4 ++ ++ + ND  ND  ND 927.35 ± 17.00
4T1 ++ + + ND  ND  ND 1,523.25 ± 162.8
Veh, vehicle; Ruxo, Ruxolitinib; ND, not determined.
aActivation of STAT3 and SMDA2 transcription factors induced in fibroblasts by tumor cell CM was assessed by western blot. Detectable (+) or
undetectable () phosphorylation.
bContractility and proinvasive activities induced in fibroblasts by tumor cell CMwere determined using three-dimensional collagen lattices and organo-
typic invasion assays. Induction (+); no induction ().
cLIF was detected by ELISA.
dLIF and TGF-b blocking antibodies were used either at 10 mg/ml or as stated.expression (Figure 4C), whereas 67NR CM failed to activate
SMAD2 and STAT3 and to induce a-SMA expression (Fig-
ure 4C). In vivo, a-SMA expression was detected within the tu-
mor mass of 410.4 tumor microenvironment but not within
67NR tumor, suggesting a strong correlation between the
in vitro and in vivo situations (Figures 4Be and f). In tumors,
collagen fibers are indicative of a dense ECM and correlate1670 Cell Reports 7, 1664–1678, June 12, 2014 ª2014 The Authorswith the invasive potential of tumor cells (Levental et al., 2009;
Paszek et al., 2005; Samuel et al., 2011). Assessment of
collagen production (Figures 4Bg and h) and collagen fibers as-
sembly (Figures 4Bi–j) in xenograft tumors by Sirius Red stain-
ing disclosed enhanced decoration in 410.4 tumors compared
with 67NR tumors, with formation of polarized collagen fibers
(Figures 4Bi and j and 4D).
Figure 4. LIF and JAK Signaling Mediate Malignant Tumor Microenvironment In Vivo
(A) ELISA quantification of LIF secreted in mouse breast cancer cells culture media. (UD, undetectable; n = 3 in duplicates). Bottom panel shows the cell invasion
and metastatic capacities (Y, yes; N, no).
(B) Immunohistological staining of LIF, p-STAT3, a-SMA, Sirius Red (scale bar, 100 mm), and polarized collagen fibers (scale bar, 50 mm) in orthotopic 67NR and
410.4 mouse breast cancer models 30 days after injection.
(legend continued on next page)
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To disclose the fundamental role of JAK kinase activity in
fibroblasts-mediated proinvasive ECM remodeling, we further
assessed the effect of the JAK1/2 inhibitor Ruxolitinib on tumor
microenvironment development in vivo by 21 day oral gavage
of mice implanted with 410.4 cells. The drug inhibited STAT3
phosphorylation both within the tumor microenvironment in vivo
(Figure 4Bl) and in vitro (Figure 4C), without influencing LIF
production (Figure 4Bk) or a-SMA staining (Figure 4Bm). JAK
signaling inhibition reduced Sirius Red staining (Figure 4Bn)
and formation of collagen bundles (Figures 4Bo and 4D), which
underscores the role of JAK in collagen fibers assembly within
the tumor microenvironment in vivo, with no detectable inci-
dence of Ruxolitinib treatment on tumor size in vivo (Figure 4E)
and 410.4 cells proliferation in vitro (Figure S4B). Consistent
with the fact that matrix stiffness promotes tumor cell invasion
in vitro and in vivo (Goetz et al., 2011; Levental et al., 2009; Pas-
zek et al., 2005; Provenzano et al., 2008), we disclosed that in
mice treated with Ruxolitinib the tumor cells displayed a signifi-
cant reduced rates of invasion (Figures 4F and 4G).
We next unveiled the collaborative role of both TGF-b and
JAK/ROCK signaling during ECM remodeling in vitro. In hDF,
and opposite to LIF stimulation (Figure S4Ca–d), fibronectin
expression pattern was upregulated by TGF-b1 stimulation (Fig-
ures S4Ce and f) and slightly reduced after addition of P6 inhib-
itor (Figures S4Cg and h). Moreover, TGF-b1-stimulated hDF
exhibited an enhanced fibronectin secretion and deposition
into the matrix compared to LIF-stimulated and control hDF
(Figure S4D). Further, JAK inhibition was ineffective on fibro-
nectin secretion but dramatically reduced its assembly into
the matrix (Figure S4D), whereas forced ROCK activation, in
absence of JAK activity, rescued proper fibronectin assembly
(Figure S4E). Taken together, these data disclose a collabora-
tive role of TGF-b1 and JAK/ROCK signaling in fibroblast-
dependent ECM remodeling and matrix protein assembly. We
also demonstrated that TGF-b1-stimulated mouse dermal fibro-
blasts secrete LIF in the culture media (Figure S4F), which leads
to collagen gel contraction in vitro (Figure S4G) and in autocrine
activation of STAT3 phosphorylation (Figure S4H). Blockade of
JAK kinase activity, by either addition of Ruxolitinib or LIF
sequestration using a specific blocking antibody, resulted in
both complete abrogation of STAT3 phosphorylation (Fig-
ure S4H) and matrix remodeling (Figure S4G). Thus, the mice
xenograft breast cancer model demonstrated that LIF, indepen-
dently of a-SMA expression, supports tumor stroma remodeling
and that Ruxolitinib by inhibiting JAK, abrogates the proinvasive
crosstalk between tumor and stroma cells both in vitro and
in vivo.(C) Immunoblotting of a-SMA, p-STAT3, and p-SMAD2 in mouse dermal fibrobla
presence of LIF blocking antibody and Ruxolitinib inhibitor at 10 mg/ml or 10 mM
tubulin as controls.
(D) Quantification of collagen bundles surface (thickness3 length in mm2) shown in
410.4 = 680, and 410.4 + Ruxo = 390.
(E) Representative images of 410.4 orthotopic tumors following Ruxolitinib treatm
(F) H&E coloration of paraffin-embedded sections of 410.4 orthotopic tumors follow
pad adjacent the tumor mass. Scale bar, 125 mm.
(G) Quantification of tumor invasion shown in (E). Distance was calculated using
condition (mean ± SD; p = 0.000045).
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Correlates with Invasive Tumor Microenvironment
Formationand Poor Clinical Outcome
Randomized analysis of 117 biopsies from human carcinomas,
including skin (n = 17), head and neck (n = 50), and lung (n =
50) carcinomas (Table S2), detected strong diffused LIF staining
compared to control immunoglobulin (Ig) G or to skin control tis-
sues where LIF expression is confined to basal keratinocytes
(Figures 5A and 5B). Subsequent investigation of tumor-stroma
remodeling by Sirius Red staining, and observation under polar-
ized light, disclosed collagen fiber organization in human tumors
expressing both high and low LIF levels. Thus LIF upregulation
clearly correlated with marked assembly of collagen bundles
(Figures 5C, 5D, S5A, and S5B) and significantly poor clinical
outcome for patients with head and neck and lung carcinomas
(Figures 5E and 5F). Further, correlation between LIF detection,
Sirius Red staining and presence of invasion nodules was
observed in 100 carcinomas (Figure S5C and S5D). Taken
together, these data validate our in vitro evidence linking LIF
expression to fibroblast-dependent proinvasive ECM remodel-
ing in cancer.
Ruxolitinib Is a Potent Inhibitor of Proinvasive Tumor
Microenvironment Remodeling
To confirm the results obtained with mice, the inhibitory effect of
Ruxolitinib on collective carcinoma cell invasion was assessed
in vitro. The drug (5–10 mM) prevented track formation and
SCC12 cell invasion promoted by hCAF (Figures 6A–6C) by in-
hibiting the CAF endogenous STAT3 activity (Figure 6D). More-
over, Ruxolitinib completely inhibited both TGF-b1- and LIF-
dependent activation of hDF contractility in collagen-rich lattices
(Figure S6A) and also abrogated proinvasive hDF activation
induced upon TGF-b1 and LIF stimulation (Figures S6B and
S6C) by repressing STAT3 phosphorylation in TGF-b1- or LIF-
stimulated fibroblasts with no effect on SMAD2 (Figure S6D).
Because part of the Cyt387 JAK inhibitor effects (Figure S1D)
may be due to direct ROCK2 inhibition (Pardanani et al., 2009),
we specifically assessed whether effects of Ruxolitinib could
be mediated by inhibition of ROCK activity. Forced expression
of an active form of ROCK (ROCK-ER) (Croft and Olson, 2006)
following 4-hydroxytamoxifen (4OHT) treatment induced MLC2
phosphorylation (Figure S6E) and SCC12 cells invasion (Fig-
ure S6F) regardless of Ruxolitinib treatment. However, specific
ROCK inhibitors treatment following 4OHT abrogated both
SCC12 cell invasion (Figure S6F) and MLC2 phosphorylation
(data not shown), therefore, excluding the possibility of nonspe-
cific activity of Ruxolitinib on ROCK activity. Therefore, use of thest long-term stimulated (7 days) using 67NR and 410.4 CM in the absence or
final concentration, respectively. Immunoblotting of total STAT3, SMAD2, and
Bi, j, and o (each dot represents one fibers). Total quantified fibers: 67NR = 96,
ent showing tumor within the mammary fat pad.
ing Ruxolitinib treatment showing tumor cells invasion within themammary fat
ImageJ software by the mean of five measurements from 18 pictures for each
Figure 5. LIF Overexpression inHumanSkin
SCC Tumors Correlates with Assembled
Collagen Fiber Organization
(A) LIF immunohistological staining in human
normal skin (h. Skin) and carcinomas from mul-
tiple origins (h. Skin SCC tumor n = 17; head
and neck carcinomas n = 50 and lung carci-
nomas n = 50). IgG staining as control. Scale bar,
100 mm.
(B) Quantification of mean Quick Score from
tumors shown in (A).
(C) Quantification of collagen fibers density in
tumors expressing low and high LIF levels in head
and neck and lung carcinomas (mean ± SD of
three pictures from ten independent tumors per
condition, ***p < 0.001).
(D) Sirius Red collagen bundles observed
under polarized light in tumors expressing low
and high LIF levels quantified in (C). Scale bar,
100 mm.
(E) Kaplan-Meier survival over time of patients with
head and neck carcinomas expressing low (n = 23)
and high (n = 27) LIF levels.
(F) Kaplan-Meier survival over time of patients with
lung carcinomas expressing low (n = 23) and high
(n = 27) LIF levels.JAK1/2 kinase inhibitor Ruxolitinib may pave the way to thera-
peutic approaches aiming at thwarting not only cancer invasion,
but also stroma activation during the early steps of aggressive
carcinomadevelopment. To this respect, collagen bundle forma-
tion by hDF was verified in vitro using 3D-organotypic cultures.
hDF stimulated by either TGF-b1 or LIF showed an enhanced ca-
pacity to assembly polarized collagen fibers, whichwas inhibited
by Ruxolitinib (Figures 6E and 6F), which provides further evi-
dence for the role of fibroblast JAK kinase in tumor ECM
remodeling.Cell Reports 7, 1664–167DISCUSSION
We identify LIF, a member of the IL-6
proinflammatory cytokine family, as the
main driver of proinvasive TGF-b-depen-
dent evolution of the tumor microenviron-
ment. LIF mediates autocrine TGF-b1-
dependent proinvasive activation in fibro-
blasts, whereas, in a paracrine manner,
tumor-secreted LIF promotes and sus-
tains proinvasive conversion of fibroblast
independent of a-SMA expression. LIF is
overexpressed in a variety of solid tumors
including skin cancers (Garcı´a-Tun˜o´n
et al., 2008; Wysoczynski et al., 2007)
and LIF production by tumor cells corre-
lates with their invasive potential (Aslak-
son and Miller, 1992; Clark et al., 2000).
However, downregulation of LIFr recently
reported in cancer cells (Chen et al.,
2012) prompted the idea that tumor cell-
derived LIF may exert paracrine effect intumorigenesis. Here, we propose that paracrine activities of
LIF are related to stromal fibroblast proinvasive activation.
CAFs are key players of cancer-associated inflammatory pro-
cesses (Erez et al., 2010; Orimo et al., 2005). Secretion of IL-11
upon TGF-b stimulation of CAFs was shown to induce GP130-
IL6ST/STAT3 signaling in colorectal cancer, which confers a sur-
vival advantage to metastatic cells and leads to increased effi-
ciency of organ colonization (Calon et al., 2012). Our results,
showing that TGF-b1-mediated LIF secretion both in tumor cells
and fibroblasts, emphasize the action of TGF-b1 as a driver of8, June 12, 2014 ª2014 The Authors 1673
Figure 6. Ruxolitinib Prevents hCAF-Dependent Proinvasive Matrix Remodeling In Vitro
(A) Quantification of SCC12 cells invasion induced by hHN-CAF in presence of Ruxolitinib inhibitor at a stated range concentrations.
(B) H&E coloration of paraffin-embedded sections of SCC12 cells quantified in (A). Scale bar, 100 mm.
(C) H&E coloration of paraffin-embedded sections of SCC12 cells in response to three hCAF (HN, Lu, and Br) in presence or absence (veh.) of 10 mMRuxolitinib.
(I.I., invasion index; n = 3; mean ± SD; ***p < 0.001.) Scale bar, 100 mm.
(legend continued on next page)
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tumor-associated inflammation, which is a key step for stromal
fibroblast proinvasive activation. LIF transcription regulation by
TGF-b1 was recently implicated in glioblastoma tumor-initiating
cell renewal (Pen˜uelas et al., 2009), which suggests a general
regulation of LIF by TGF-b1 in cancer.
a-SMA expression, which is hallmark of CAFs (Kalluri and
Zeisberg, 2006), is regulated by TGF-b-dependent signaling
(Desmoulie`re et al., 1993), regulates fibroblasts contractility
(Hinz et al., 2001), and correlates with poor clinical outcome
in human tumors (Yamashita et al., 2012). Here, we provide
evidence that LIF-stimulated dermal fibroblasts, independent
of a-SMA expression, promote collagen gel contractility
in vitro and that blockade of JAK activity in vivo results in inhi-
bition of tumor-associated collagen network. LIF-activated
dermal fibroblasts acquire a contractile phenotype via a
crosstalk between the JAK1/STAT3 and RhoA/ROCK/MLC2
signaling pathways, suggesting that a-SMA and Rho-depen-
dent contractility may be regulated by two distinct mechanisms
both resulting in cell contractility and ECM remodeling. Within
the tumor microenvironment, hCAF are highly heterogeneous,
and a-SMA is not expressed by all hCAF cells (Sugimoto
et al., 2006). Moreover, PDGFRa has been proposed to be a
robust marker for CAFs in a mice model of skin cancer (Erez
et al., 2010). Similarly, we noted an increased expression of
PDGFRa after LIF stimulation in hPDF (data not shown). In light
of our results, we propose that LIF generates subpopulations
of CAF cells prone to malignancy independently of a-SMA
expression. This may imply that monitoring a-SMA expression
is not a criterion sufficient to disclose presence of all the proin-
vasive fibroblasts within the tumor stroma, which thus may lead
to biased favorable prognosis for patients. In contrast, high
expression of LIF cytokine in patients with both head and
neck or lung carcinomas better correlates with poor clinical
prognosis (Figures 5E and 5F).
Actomyosin contractility is crucial for CAF-dependent proin-
vasive matrix remodeling (Gaggioli et al., 2007). We now provide
direct evidence that LIF supports TGF-b1-dependent actomy-
osin contractility in hPDF. Accordingly, formation of collagen
fibers in tumors is indicative of ECM densification and correlates
with acquisition of invasive potential by tumor cells (Levental
et al., 2009; Paszek et al., 2005; Samuel et al., 2011). Similar to
human SCC tumors overexpressing LIF, in vivo orthotopic
mouse breast cancer model and hDF in vitro cell cultures
disclose that LIF and JAK drive TGF-b1-induced dense collagen
fibers remodeling in vivo and in vitro through RhoA and MLC2
overexpression in hDF, which results in increased MLC2 phos-
phorylation and actomyosin contractility. Actomyosin contrac-
tility induces matrix stiffening (Samuel et al., 2011) and,
conversely, stiff matrix activates YAP/TAZ and RhoA/ROCK-
dependent signaling pathways in CAFs (Calvo et al., 2013) and
favors tumor cell invasion (Calvo et al., 2013; Goetz et al.,
2011; Levental et al., 2009; Paszek et al., 2005; Provenzano(D) Immunoblotting of p-STAT3 and p-SMAD2 in three hCAF (HN, Lu and Br) cel
SMAD2, and tubulin shown as controls.
(E) Sirius Red staining of SCC12 cell organotypic invasion assays in presence of
Ruxolitinib. Top and bottom panels show Sirius Red staining under normal and p
(F) Quantification of thickness and length of collagen bundles shown in (E).
Cet al., 2008). We now show that forced expression of a constitu-
tively activated ROCK protein is sufficient to induce proinvasive
fibroblasts activity in vitro. This loop may constitute a mecha-
nism by which hPDF is also activated during tumorigenesis
(Calvo et al., 2013). In this context, TGF-b signaling drives fibro-
nectin extracellular matrix protein expression, whereas JAK1
kinase activity, by regulating actomyosin contractility, is respon-
sible for protein assembly into the matrix, which suggests a
collaborative role for both TGF-b and JAK signaling pathways
in tumor fibrosis. This finding is in agreement with the fact that
JAK2 drives the profibrotic effect of TGF-b signaling in systemic
sclerosis and cutaneous fibrosis (Canady et al., 2013; Dees et al.,
2012), a process also implying STAT3 in lung fibrosis (O’Donog-
hue et al., 2012). Because fibrosis is known to be mediated by
excessive ECM remodeling and collagen fiber assembly (Wynn
and Ramalingam, 2012), it is conceivable that the JAK1/STAT3
signaling route supports the hCAF profibrotic activity in cancer,
which results in a matrix prone to collective cancer cell invasion.
In light of our data, we propose that, via still undefined mecha-
nisms, constitutive activation of STAT3 may occur in hCAF,
which influences invasiveness of human cancers. Accordingly,
blockade of JAK activity by the JAK1/2 inhibitor Ruxolitinib coun-
teracts the TGF-b- and LIF-mediated fibroblast-dependent col-
lective carcinoma cell invasion in vitro and in vivo. Ruxolitinib
has been approved by the Food and Drug Administration for
treatment of patients with intermediate or high-risk myelofibrosis
(Mascarenhas and Hoffman, 2012), and this drug is also in a
phase II clinical trial for patients with breast or pancreatic cancer
in which STAT3 is frequently constitutively activated (Berishaj
et al., 2007; Scholz et al., 2003). Therefore, clinical use of the
JAK1/2 Ruxolitinib inhibitor may be a promising approach in
combination with chemotherapies for patients suffering from
aggressive cancers through the targeting of stromal fibroblasts
and ECM-associated remodeling events.
In conclusion, our work reveals a novel role of LIF in malig-
nancy. LIF signaling in fibroblasts results in proinvasive tumor
microenvironment promotion and mediates TGF-b-dependent
fibrosis in cancer. We speculate that blockade of JAK kinase
activity within the tumor mass may constitute a promising thera-
peutic approach to counteract the CAF-dependent protumori-
genic ECM remodeling.EXPERIMENTAL PROCEDURES
Organotypic Invasion Assays
hDF or CAFs cultured during 1 week in serum-free medium (with either
vehicle or cytokines) or CM were embedded in matrix gel. Fibroblasts (5 3
105) were embedded in a 1 ml mixture of collagen I and Matrigel (Gaggioli
et al., 2007).
Invasion assay was defined bymeasuring the total areas of SCC cells versus
noninvading SCC cells using ImageJ software (http://rsbweb.nih.gov/ij/). The
value of invasion index is the average 1  (noninvading area/total area) of at
least ten fields from three or more independent experiments.ls compared to hDF in presence of 10 mM Ruxolitinib. Immunoblots of STAT3,
hDF control (Veh.) or stimulated by LIF and TGF-b1 in presence or absence of
olarized light respectively. Scale bar, 100 mm.
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Matrix Remodeling Assay
Fibroblasts (2.5 3 104) were embedded in 100 ml of matrix gel (Hooper et al.,
2010). After 1 hr at 37C, matrices were overlaid with 100 ml serum-free me-
dium (with vehicle or cytokines and/or inhibitors) or CM. Every 2 days, me-
dium was changed, and at day 6 gels were photographed and the respective
diameters of the well and gel were measured using ImageJ. The contraction
was calculated using the formula 100 3 (well diameter – gel diameter)/well
diameter.Orthotopic Tumors in BALB/c Mice
Six- to 8-week-old female BALB/cmicewere anesthetized using ketamine and
xylazine by peritoneal injection. Skin was incised and 5 3 103 67NR or 410.4
cells were injected into the right and left fourth mammary fat pad in 10 ml of
PBS for eachmouse. 67NR group consisted of twomice (four primary tumors),
410.4 group of seven mice (14 tumors), and 410.4 with additional treatment of
Ruxolitinib (30 mg/kg/day) group of five mice (ten tumors). Mice were sacri-
ficed 30 days postinjection, and Ruxolitinib treatment started 7 days after in-
jection; primary tumors were removed and fixed in PBS containing 3.7%
formalin for 8 hr, followed by PBS and transfer to 70% ethanol, and then
embedded in paraffin and sectioned and stained with hematoxylin and eosin.
Immunohistochemistry detection using anti-LIF, anti-p-STAT3, and anti-
alpha-SMA antibodies was performed on paraffin sections following manufac-
turer’s instructions. The protocol was approved by the local ethic committee of
the IRCAN institute.
LIF Immunohistological Staining
Formalin-fixed tissues (3.7% in PBS) were transferred to 70% ethanol,
embedded in paraffinwax, and sectioned at 7 mm.After deparaffination,micro-
wave antigen retrieval wasperformed inNa-citrate buffer (10mM [pH6] 5min at
900 W and 25 min at 150 W), and sections were washed in PBS. Endogenous
peroxidase activity was then blocked in 1%H2O2 in water for 10 min and sec-
tions were washed. After incubation in blocking buffer for 2 hr (10% rabbit
serum [S-5000, Vector Laboratories]; 0.3% Triton X-100 in PBS), sections
were incubated with LIF primary antibody (#sc-1336, Santa Cruz Biotech-
nology) diluted 1:50 in blocking buffer overnight at 4C. For negative controls,
rabbit IgG replaced the primary antibody. After three washes in PBS, sections
were incubatedwith biotinylated anti-goat IgG (#BA-5000, Vector Labs) diluted
1:400 in PBS for 30 min and washed in PBS. Samples were processed using
Vectastain ABC kit (#PK4001, Vector Labs) and DAB peroxidase substrate
kit (#SK4100, Vector Labs) according to manufacturer’s instructions. Sections
were counterstained with hematoxylin for 5 s, rinsed in water, blued 10 s in
0.08% ammonia water, dehydrated, cleared, and mounted with cover clips.
LIF Staining, Fibrosis, and Tumor Invasion Quantification Method
The protocol was approved by the local ethic committee of the Nice University
Hospital. All patients signed an informed consent for inclusion into a research
project. All the observations on tumor samples were performed by indepen-
dent double-blind examiners. The Quick Score (QS) with a 0–16 point scale
was used to score the LIF cytokine status within the tumor cells. The QS takes
into account both the percentage of positive cells (P, with a 0–4 point scale)
and the corresponding staining intensity (I, with a 0–4 point scale) using the for-
mula: QS =P3 I. Sirius red staining observed under polarized light was used to
score fibrosis within the samples with a 0–4 point scale (0 = no staining; 4 =
very strong staining). Fibrosis was quantified on low and high fibrotic samples
as determined before bymeasuring themean gray valuewith ImageJ software.
Invasion of cancer cells was scored using a 0- to 4-point scale (from 0 = no in-
vasion, to 4 = strong invasion of tumor cells). The number of invasive collective
strands and sheets within the stroma was used to score the samples.
Statistical Analysis
Student’s t test was performed for quantifications of invasion assay, matrix re-
modeling assay, ELISA test, and quantitative PCR results (***p < 0.001; **p <
0.01; *p < 0.05).
Kaplan-Meier survival curves were obtained using the PRISM software by
comparing two groups of high and low LIF-expressing tumors; p values
were obtained using Gehan-Breslow-Wilcoxon test.1676 Cell Reports 7, 1664–1678, June 12, 2014 ª2014 The AuthorsSUPPLEMENTAL INFORMATION
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